Company: BIAF
Filing Date: 2025-05-23
Form Type: PRER14A
Source: 0001641172-25-012315
Chunk: 23

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-23
Form: PRER14A
Chunk 23
---
 the Company’s independent auditor;
(v) reviewing and discussing with the Company’s independent auditor all critical accounting policies and practices to be used in
the Company’s audit; (vi) reviewing the internal quality control procedures of the Company’s independent auditor and any material
issues raised by the most recent internal quality control review, peer review, or Public Company Accounting Oversight Board (“PCAOB”)
review or inspection of the firm; (vii) reviewing all related-party transactions; and (viii) monitoring the Company’s compliance
with all legal and regulatory requirements. A copy of the charter of the Audit Committee is available on the Investor Relations section
of the Company’s website at ir.bioaffinitytech.com and can be accessed through the “Governance Documents” hyperlink
under the “Governance” tab.

The Audit Committee has reviewed and discussed the
Company’s audited financial statements for the fiscal year ended December 31, 2024, with the Company’s management. The Audit
Committee has discussed with the Company’s independent registered public accounting firm, WithumSmith+Brown, PC, the matters required
to be discussed by the applicable requirements of the PCAOB and the SEC. The Audit Committee has also received the written disclosures
and the letter from the independent registered public accounting firm required by applicable PCAOB requirements regarding the independent
accountants’ communications with the Audit Committee concerning independence and has discussed with the independent registered public
accounting firm its independence.

Based on the review and discussions with management
and the Company’s independent auditor referenced above, the Audit Committee has recommended to the Board that the audited consolidated
financial statements be included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the
SEC.

This report by the Audit Committee shall not be deemed
incorporated by reference by any general statement incorporating by reference this Proxy Statement into any filing under the Securities
Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates this information by
reference and shall not otherwise be deemed filed under such acts.

Submitted by the Audit Committee of the Board of Directors:

Mr. Stuart Diamond (Chairman)

Mr. Gary Rubin

Mr. Robert Anderson

| 15 |

<div align='center'>PROPOSAL NO. 3

APPROVAL OF THE REVERSE STOCK SPLIT</div>

The Board of Directors has adopted a
resolution setting forth a proposed amendment to our Certificate of Incorpor